Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LS1209
- Development stage
- Unknown
- Lead developer
- Washington University in St. Louis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
LS1209: sourced facts only. name: "Our lab has previously developed a peptide-based radiotracer (LS1209) that targets CD38 for specific and sensitive imaging in MM." [DOI:10.1158/1538-7445.am2025-4472]; target: "Our lab has previously developed a peptide-based radiotracer (LS1209) that targets CD38 for specific and sensitive imaging in MM." [DOI:10.1158/1538-7445.am2025-4472]; developer: "Washington University in Saint Louis, Saint Louis, MO." [DOI:10.1158/1538-7445.am2025-4472]; modality: "Our lab has previously developed a peptide-based radiotracer (LS1209) that targets CD38 for specific and sensitive imaging in MM." [DOI:10.1158/1538-7445.am2025-4472]
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on LS1209.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LS1209.